Clinical progress note: Haemophilus influenzae type b
- PMID: 40205699
- DOI: 10.1002/jhm.70059
Clinical progress note: Haemophilus influenzae type b
Abstract
Vaccine-preventable diseases that have yet to be eliminated are important to review for the practicing clinician. Haemophilus influenzae type b (Hib) was once the leading cause of bacterial meningitis in young children and now causes rare invasive disease in young children and the elderly. Patients with immunodeficiency and impaired complement response to encapsulated organisms (e.g., sickle cell disease; asplenia) are at particular risk of invasive Hib disease. Recognition of a potential case, prompt management and reporting, and inpatient vaccine administration and education are crucial actions for hospitalists in the management of Hib disease and prevention.
© 2025 Society of Hospital Medicine.
References
REFERENCES
-
- Cochi SL. Immunization of US children with Hemophilus influenzae type b polysaccharide vaccine. A cost‐effectiveness model of strategy assessment. JAMA. 1985;253(4):521‐529.
-
- Slack MPE, Cripps AW, Grimwood K, Mackenzie GA, Ulanova M. Invasive Haemophilus influenzae infections after 3 decades of Hib protein conjugate vaccine use. Clin Microbiol Rev. 2021;34(3):e0002821. doi:10.1128/CMR.00028-21
-
- Briere EC, Rubin L, Moro PL, et al. Prevention and control of Haemophilus influenzae type b disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2014;63(RR‐01):1‐14.
-
- Broome CV. Epidemiology of Haemophilus influenzae type b infections in the United States. Pediatr Infect Dis J. 1987;6(8):779‐782. doi:10.1097/00006454-198708000-00036
-
- Wenger JD. Epidemiology of Haemophilus influenzae type b disease and impact of Haemophilus influenzae type b conjugate vaccines in the United States and Canada. Pediatr Infect Dis J. 1998;17(9 suppl):S132‐S136. doi:10.1097/00006454-199809001-00008
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
